CSOP Hang Seng Biotech ETF (03174.HK) fell 0.23% to HKD 3.496

Newtimespace News, as of 14:15 on May 6, CSOP Hang Seng Biotech ETF (03174.HK) was quoted at HKD 3.496, down 0.23%. The ETF opened at HKD 3.504, with a high of HKD 3.522 and a low of HKD 3.460. The latest trading volume was 1.0639 million units, with a turnover of HKD 3.7155 million, and a turnover rate of 0.42%. The latest NAV per unit is HKD 3.511, with a premium rate of -0.19%. The asset size is approximately HKD 891 million, and the total issuance is 254 million units.

CSOP Hang Seng Biotech ETF (03174.HK) tracks the Hang Seng Biotech Index, which is compiled and published by Hang Seng Indexes Company Limited. The index was launched in December 2019 and aims to track the overall performance of the 30 largest eligible biotech companies listed in Hong Kong that are also eligible for Southbound Stock Connect trading. The index is calculated using the market capitalization weighting method. Its constituents broadly cover four main business sub-categories: pharmaceuticals, biotechnology, drug distribution, and medical equipment and supplies, with a deep focus on core biotech innovation areas such as innovative drugs, CXO (Contract Research, Development and Manufacturing Organizations), and medical devices. This ETF provides investors with a high-purity tool for concentrated investment in leading Hong Kong-listed biotech companies and for capturing national trends in pharmaceutical innovation. It features a high degree of industry concentration and is accompanied by the high R&D investment and market volatility characteristic of the biotech sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.